MX336346B - Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa. - Google Patents
Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa.Info
- Publication number
- MX336346B MX336346B MX2013007702A MX2013007702A MX336346B MX 336346 B MX336346 B MX 336346B MX 2013007702 A MX2013007702 A MX 2013007702A MX 2013007702 A MX2013007702 A MX 2013007702A MX 336346 B MX336346 B MX 336346B
- Authority
- MX
- Mexico
- Prior art keywords
- glycogen synthase
- synthase kinase
- treatment
- heterocyclic compounds
- inhibitors
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 239000003572 glycogen synthase kinase 3 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000001267 GSK3 Human genes 0.000 abstract 2
- 108091007911 GSKs Proteins 0.000 abstract 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 abstract 2
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061428478P | 2010-12-30 | 2010-12-30 | |
| US201161521868P | 2011-08-10 | 2011-08-10 | |
| PCT/EP2011/074272 WO2012089828A2 (en) | 2010-12-30 | 2011-12-30 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013007702A MX2013007702A (es) | 2013-11-20 |
| MX336346B true MX336346B (es) | 2016-01-15 |
Family
ID=45524498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013007702A MX336346B (es) | 2010-12-30 | 2011-12-30 | Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9090592B2 (enExample) |
| EP (2) | EP2658854B1 (enExample) |
| JP (2) | JP6144201B2 (enExample) |
| KR (1) | KR101860297B1 (enExample) |
| CN (1) | CN103476766B (enExample) |
| AU (1) | AU2011351375B2 (enExample) |
| BR (1) | BR112013016928A2 (enExample) |
| CA (1) | CA2821863A1 (enExample) |
| IL (1) | IL226676A (enExample) |
| MX (1) | MX336346B (enExample) |
| NZ (1) | NZ611314A (enExample) |
| RU (1) | RU2623427C2 (enExample) |
| SG (2) | SG10201406098UA (enExample) |
| WO (1) | WO2012089828A2 (enExample) |
| ZA (1) | ZA201304756B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642598B2 (en) * | 2006-10-21 | 2014-02-04 | Abbvie Inc. | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| CN103119035B (zh) | 2010-09-27 | 2015-09-30 | 雅培股份有限两合公司 | 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途 |
| US9090592B2 (en) * | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| JP6534098B2 (ja) * | 2014-09-12 | 2019-06-26 | 国立大学法人 鹿児島大学 | 成人ｔ細胞白血病治療薬 |
| EP3592731A4 (en) * | 2017-03-08 | 2020-10-07 | Cornell University | MALT1 INHIBITORS AND THEIR USES |
| RU2739489C2 (ru) * | 2018-03-06 | 2020-12-24 | Закрытое Акционерное Общество "Биокад" | Новые гетероциклические соединения как ингибиторы CDK8/19 |
| CN112823006B (zh) * | 2018-10-17 | 2024-09-17 | 杜克大学 | 用作神经保护剂的醌还原酶2抑制剂 |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| IL291996B2 (en) * | 2019-11-01 | 2026-01-01 | Syngenta Crop Protection Ag | Molten bicyclic heteroaromatic compounds active as pesticides |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| BR112023000047A2 (pt) | 2020-07-02 | 2023-03-14 | Incyte Corp | Compostos de ureia tricíclicos como inibidores da v617f da jak2 |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| KR20240163688A (ko) | 2022-03-17 | 2024-11-19 | 인사이트 코포레이션 | Jak2 v617f 억제제로서의 삼환계 우레아 화합물 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
| AUPP003197A0 (en) * | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| US6417185B1 (en) | 1998-06-19 | 2002-07-09 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| GT200100147A (es) | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| NZ523656A (en) | 2000-08-31 | 2004-11-26 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| ES2266258T3 (es) | 2000-09-15 | 2007-03-01 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de proteina cinasas. |
| ATE400287T1 (de) | 2001-04-30 | 2008-07-15 | Aeterna Zentaris Gmbh | Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit |
| DE10123586A1 (de) | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| DE60208630T2 (de) | 2001-05-11 | 2006-08-17 | Pfizer Products Inc., Groton | Thiazolderivate und ihre Verwendung als cdk-Inhibitoren |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| JP5039268B2 (ja) | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| CA2469316A1 (en) | 2001-12-07 | 2003-06-19 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as gsk-3 inhibitors |
| SE0104341D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| AU2002359162A1 (en) | 2001-12-21 | 2003-07-15 | Astrazeneca Ab | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 |
| SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| WO2004072029A2 (en) | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
| WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| CA2536253A1 (en) | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | Aminofurazan compounds useful as protein kinase inhibitors |
| WO2005061516A1 (en) | 2003-12-04 | 2005-07-07 | Smithkline Beecham Corporation | Novel chemical compounds |
| WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1586318A1 (en) | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
| PL1737850T3 (pl) | 2004-04-19 | 2008-02-29 | Symed Labs Ltd | Nowy sposób wytwarzania linezolidu i związków pokrewnych |
| CA2569404A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| JP2008502687A (ja) | 2004-06-14 | 2008-01-31 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| EP1781653A1 (en) | 2004-07-05 | 2007-05-09 | Astex Therapeutics Limited | 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors |
| WO2006008754A1 (en) | 2004-07-20 | 2006-01-26 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| EP1804823A4 (en) | 2004-09-29 | 2010-06-09 | Amr Technology Inc | NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| BRPI0612888B8 (pt) | 2005-06-30 | 2022-12-27 | Janssen Pharmaceutica Nv | anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica |
| EP1749523A1 (en) | 2005-07-29 | 2007-02-07 | Neuropharma, S.A. | GSK-3 inhibitors |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| UY29825A1 (es) | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones |
| US20090170847A1 (en) | 2006-01-23 | 2009-07-02 | Seung Chul Lee | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same |
| JP2009525325A (ja) | 2006-02-02 | 2009-07-09 | アストラゼネカ・アクチエボラーグ | ２−ヒドロキシ−３−［５−（モルホリン−４−イルメチル）ピリジン−２−イル］１ｈ−インドール−５−カルボニトリルの遊離塩基又は塩としての医薬用途 |
| WO2007120102A1 (en) | 2006-04-19 | 2007-10-25 | Astrazeneca Ab | New substituted oxindole derivatives |
| EP1849785A1 (en) | 2006-04-28 | 2007-10-31 | Neuropharma, S.A. | N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors |
| US7622495B2 (en) | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| US8642598B2 (en) * | 2006-10-21 | 2014-02-04 | Abbvie Inc. | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| JP2010513567A (ja) | 2006-12-19 | 2010-04-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なアミノピリミジン |
| ES2446269T3 (es) | 2006-12-19 | 2014-03-06 | The Board Of Trustees Of The University Of Illinois | 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| BRPI0810216A2 (pt) | 2007-04-18 | 2014-10-21 | Astrazeneca Ab | Processo para a preparação de composto, composto, e, método de tratamento de distúrbio bipolar |
| KR20100105802A (ko) | 2007-04-19 | 2010-09-29 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 모르폴리닐 화합물 |
| EP1992624A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| BRPI0811065A2 (pt) * | 2007-06-08 | 2014-12-02 | Abbott Lab | Indazóis 5-heteroaril substituídos como inibidores de quinase |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090137457A1 (en) | 2007-10-02 | 2009-05-28 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| AU2008317375B2 (en) | 2007-10-26 | 2013-02-28 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| US8455648B2 (en) * | 2008-04-24 | 2013-06-04 | Abbott Gmbh & Co. Kg | 1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3) |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) * | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
-
2011
- 2011-12-29 US US13/339,884 patent/US9090592B2/en not_active Expired - Fee Related
- 2011-12-30 SG SG10201406098UA patent/SG10201406098UA/en unknown
- 2011-12-30 EP EP11811357.0A patent/EP2658854B1/en not_active Not-in-force
- 2011-12-30 MX MX2013007702A patent/MX336346B/es unknown
- 2011-12-30 EP EP17206645.8A patent/EP3351543A1/en not_active Withdrawn
- 2011-12-30 BR BR112013016928-1A patent/BR112013016928A2/pt not_active IP Right Cessation
- 2011-12-30 CA CA2821863A patent/CA2821863A1/en not_active Abandoned
- 2011-12-30 NZ NZ611314A patent/NZ611314A/en not_active IP Right Cessation
- 2011-12-30 SG SG2013050703A patent/SG191789A1/en unknown
- 2011-12-30 RU RU2013135477A patent/RU2623427C2/ru not_active IP Right Cessation
- 2011-12-30 CN CN201180068418.0A patent/CN103476766B/zh not_active Expired - Fee Related
- 2011-12-30 JP JP2013546715A patent/JP6144201B2/ja not_active Expired - Fee Related
- 2011-12-30 AU AU2011351375A patent/AU2011351375B2/en not_active Ceased
- 2011-12-30 KR KR1020137020021A patent/KR101860297B1/ko not_active Expired - Fee Related
- 2011-12-30 WO PCT/EP2011/074272 patent/WO2012089828A2/en not_active Ceased
-
2013
- 2013-05-30 IL IL226676A patent/IL226676A/en active IP Right Grant
- 2013-06-25 ZA ZA2013/04756A patent/ZA201304756B/en unknown
-
2015
- 2015-06-15 US US14/740,048 patent/US9540370B2/en not_active Expired - Fee Related
-
2017
- 2017-01-26 JP JP2017011851A patent/JP2017122089A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN103476766A (zh) | 2013-12-25 |
| EP2658854A2 (en) | 2013-11-06 |
| IL226676A (en) | 2015-08-31 |
| JP2014501269A (ja) | 2014-01-20 |
| WO2012089828A2 (en) | 2012-07-05 |
| US20120172376A1 (en) | 2012-07-05 |
| US9540370B2 (en) | 2017-01-10 |
| NZ611314A (en) | 2015-06-26 |
| AU2011351375B2 (en) | 2016-08-04 |
| RU2623427C2 (ru) | 2017-06-26 |
| SG10201406098UA (en) | 2014-11-27 |
| US20150274724A1 (en) | 2015-10-01 |
| JP6144201B2 (ja) | 2017-06-07 |
| KR101860297B1 (ko) | 2018-05-23 |
| SG191789A1 (en) | 2013-08-30 |
| CA2821863A1 (en) | 2012-07-05 |
| CN103476766B (zh) | 2016-08-10 |
| KR20140003518A (ko) | 2014-01-09 |
| BR112013016928A2 (pt) | 2020-10-27 |
| JP2017122089A (ja) | 2017-07-13 |
| EP2658854B1 (en) | 2017-12-13 |
| AU2011351375A1 (en) | 2013-06-20 |
| MX2013007702A (es) | 2013-11-20 |
| RU2013135477A (ru) | 2015-02-10 |
| WO2012089828A3 (en) | 2012-09-20 |
| ZA201304756B (en) | 2016-07-27 |
| US9090592B2 (en) | 2015-07-28 |
| EP3351543A1 (en) | 2018-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013007702A (es) | Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa. | |
| MX336726B (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3. | |
| MX2013001361A (es) | 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. | |
| MX2012013197A (es) | Inhibidores de indazol de cinasa. | |
| MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
| MX2012001070A (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos. | |
| MD20140109A2 (ro) | Compuşi ai indolului şi indazolului care activează AMPK | |
| TN2012000249A1 (en) | Pyrazine derivatives and their use in the treatment of neurological disorders | |
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| MX2012000709A (es) | Inhibidores de pirrolopiridina de cinasas. | |
| GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
| MX2012015252A (es) | Estimuladores de sgc. | |
| PH12014502056A1 (en) | 3,5-diaminopyrazole kinase inhibitors | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| MX2020009397A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| JOP20130256B1 (ar) | مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي | |
| MX2012000177A (es) | 2-carboxamida-cicloamino-ureas sustituidas. | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| MX2009004140A (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3. | |
| WO2009156041A3 (de) | Thiazolyl-piperidinderivate | |
| WO2009094560A3 (en) | Thienopyranones as kinase inhibitors | |
| MY152040A (en) | Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| MY148732A (en) | Triazolium salts as par1 inhibitors, production thereof, and use as medicaments |